GB2372742A - C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses - Google Patents

C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses Download PDF

Info

Publication number
GB2372742A
GB2372742A GB0105337A GB0105337A GB2372742A GB 2372742 A GB2372742 A GB 2372742A GB 0105337 A GB0105337 A GB 0105337A GB 0105337 A GB0105337 A GB 0105337A GB 2372742 A GB2372742 A GB 2372742A
Authority
GB
United Kingdom
Prior art keywords
hydrogen
mmol
compound
adenosine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0105337A
Other languages
English (en)
Other versions
GB0105337D0 (en
Inventor
Tilburg Erica W Van
Ad P Ijzerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leiden University
Original Assignee
Leiden University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiden University filed Critical Leiden University
Priority to GB0105337A priority Critical patent/GB2372742A/en
Publication of GB0105337D0 publication Critical patent/GB0105337D0/en
Priority to US10/469,735 priority patent/US7084127B2/en
Priority to EP02701520A priority patent/EP1368365A2/en
Priority to AU2002234851A priority patent/AU2002234851A1/en
Priority to JP2002569851A priority patent/JP4359676B2/ja
Priority to CA002439879A priority patent/CA2439879C/en
Priority to KR1020037011508A priority patent/KR100585894B1/ko
Priority to PCT/IL2002/000160 priority patent/WO2002070532A2/en
Priority to CNB028072014A priority patent/CN1259332C/zh
Publication of GB2372742A publication Critical patent/GB2372742A/en
Priority to US10/653,464 priority patent/US7189706B2/en
Priority to JP2008310049A priority patent/JP2009167170A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GB0105337A 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses Withdrawn GB2372742A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB0105337A GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
CNB028072014A CN1259332C (zh) 2001-03-03 2002-03-03 C2,5′－二取代的和n6，c2,5′－三取代的腺苷衍生物及其不同用途
JP2002569851A JP4359676B2 (ja) 2001-03-03 2002-03-03 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
EP02701520A EP1368365A2 (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
AU2002234851A AU2002234851A1 (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
US10/469,735 US7084127B2 (en) 2001-03-03 2002-03-03 C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses
CA002439879A CA2439879C (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
KR1020037011508A KR100585894B1 (ko) 2001-03-03 2002-03-03 Ｃ2,5'-이치환된 및 ｎ6,ｃ2,5'-삼치환된 아데노신 유도체및 그들의 상이한 용도
PCT/IL2002/000160 WO2002070532A2 (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
US10/653,464 US7189706B2 (en) 2001-03-03 2003-09-03 C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them
JP2008310049A JP2009167170A (ja) 2001-03-03 2008-12-04 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0105337A GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses

Publications (2)

Publication Number Publication Date
GB0105337D0 GB0105337D0 (en) 2001-04-18
GB2372742A true GB2372742A (en) 2002-09-04

Family

ID=9909952

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0105337A Withdrawn GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses

Country Status (9)

Country Link
US (2) US7084127B2 (cg-RX-API-DMAC10.html)
EP (1) EP1368365A2 (cg-RX-API-DMAC10.html)
JP (2) JP4359676B2 (cg-RX-API-DMAC10.html)
KR (1) KR100585894B1 (cg-RX-API-DMAC10.html)
CN (1) CN1259332C (cg-RX-API-DMAC10.html)
AU (1) AU2002234851A1 (cg-RX-API-DMAC10.html)
CA (1) CA2439879C (cg-RX-API-DMAC10.html)
GB (1) GB2372742A (cg-RX-API-DMAC10.html)
WO (1) WO2002070532A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
JP2005132767A (ja) * 2003-10-30 2005-05-26 Sumitomo Chemical Co Ltd プリン化合物の製造方法
DK1706414T3 (da) * 2003-12-22 2008-10-13 Hoffmann La Roche Fremgangsmåde til fluorcytidinderivater
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2010014921A2 (en) * 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
WO2014068589A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
CN109076162B (zh) * 2016-04-22 2020-09-22 兴和株式会社 具备复用器的拍摄装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
ES2264826T3 (es) 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
E.W. Van der Wenden et al, J.Med.Chem., (1996), 41, 102-108 *
E.W. van Tillburg et al, J.Med.Chem., (1999), 42, 1393-1400 *
H.Homma et al, J.Med.Chem., (1992), 35, 2881-2890 *
J.Matsuda et al, J.Med.Chem., (1992), 35, 241-252 *
K.Niiya et al, J.Med.Chem., (1992), 35, 4557-4561 *
S.Vittori et al, J.Med.Chem., (1996), 39, 4211-4217 *

Also Published As

Publication number Publication date
CN1537115A (zh) 2004-10-13
GB0105337D0 (en) 2001-04-18
JP4359676B2 (ja) 2009-11-04
KR100585894B1 (ko) 2006-06-07
KR20030089512A (ko) 2003-11-21
CN1259332C (zh) 2006-06-14
US7189706B2 (en) 2007-03-13
US20040132686A1 (en) 2004-07-08
US7084127B2 (en) 2006-08-01
US20040127452A1 (en) 2004-07-01
WO2002070532A2 (en) 2002-09-12
CA2439879C (en) 2009-09-15
CA2439879A1 (en) 2002-09-12
WO2002070532A3 (en) 2002-11-28
EP1368365A2 (en) 2003-12-10
JP2009167170A (ja) 2009-07-30
JP2004522794A (ja) 2004-07-29
AU2002234851A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
JP2009167170A (ja) Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
EP0708781B1 (en) A 3 adenosine receptor agonists
EP2696679B1 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BG107216A (bg) 2-аминокарбонил-9н-пуринови производни
SANEYOSHI et al. Synthetic nucleosides and nucleotides. XIII. Stannic chloride catalyzed ribosylation of several 6-substituted purines
JP2004532184A (ja) Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
WO2010068708A2 (en) 3'-azido purine nucleotide prodrugs for treatment of viral infections
CN113616659B (zh) 含有腺苷衍生物的药物组合物
KR102573609B1 (ko) 호흡기 세포융합 바이러스 rna 복제 억제제로서의 4'-비닐 치환된 뉴클레오시드 유도체
WO1998001459A1 (en) Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
EP1368364B1 (en) C2, 8-disubstituted adenosine derivatives and their different uses
WO1997033591A1 (en) A method of treating disorders related to cytokines in mammals
Takahashi et al. Synthesis and crystal structure of 2′-deoxy-2′-fluoro-4′-thioribonucleosides: substrates for the synthesis of novel modified RNAs
Seela et al. Pyrazolo [3, 4‐d] pyrimidine 2′‐Deoxy‐and 2′, 3′‐Dideoxyribonucleosides: Studies on the glycosylation of 4‐methoxypyrazolo [3, 4‐d] pyrimidine
WO1994006438A1 (en) Adenosine analogues and method of increasing adenosine release
Zhang et al. Synthesis and evaluation of 3′-azido-2′, 3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus
IL161608A (en) Synthesis and therapeutic use of 2-aralkoxyadenosines and 2-alkoxyadenosines
Marchand et al. Stereospecific synthesis of unnatural β-L-enantiomers of 2-chloroadenine pentofuranonucleoside derivatives
Sivets et al. Syntheses of Clofarabine and Related C2′-β-fluorinated Nucleoside Analogues
Mulamoottil et al. Recent Advances in Synthesis and Biological Activity of 4′‐Thionucleosides
Sivets et al. Synthesis of 2-Chloro-2′-Deoxyadenosine (Cladribine) and New Purine Modified Analogues
Mimochodková Development of selective agonists of adenosine receptors optimization of the synthetic procedures to obtain 2-chloropurine and analogues
Van Rompaey et al. Review Copy
Zhong N9 Alkylation and Glycosylation of Purines: A Practical Synthesis of 2-Chloro-2'-Deoxyadenosine
Sivets et al. SYNTHESIS OF FLUORINATED PURINE L-AND D-RIBONUCLEOSIDES

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)